Thank about you, Bob we've update everyone. an for our implemented that milestones Today, on we've a enhancements provide to about bit Thanks and and made talk the the progress good Bayview business our the joining recent afternoon, at and accomplishments further better talk I'll focus then customers. little our Advanced and revised for site full My on are I'll CIADM our program involvement and in Center Manufacturing in accompanying also X X across slides the in our summarized discuss US and year end call. to deck Development comments or the our with the the and guidance government. call. decision Innovation
started. So get let's
As as this quarter. have team you've and made resilience the strength we've their our substantial in seen year, shown Emergent progress and our business
Some the following. the of include highlights recent
work at all the of resuming significant of and production for completing end in recently made operations & Johnson we've First, on and July Bayview remaining progress more Johnson AstraZeneca. behalf
As dose million vaccine XXX COVID-XX we've for the of of of global contributed the end equivalents quarter, distribution. over
ongoing look path regulatory vaccine the while forward their their continuing support for we to to ahead, continuing support J&J's Importantly, to production months in vaccine.
medical ongoing on two from core products. commitments US key countermeasure Next the we secured government
valued modification second $XXX Strategic at and National annual received the funding Stockpile million. to of to we exercising contract nine ACAMXXXX approximately supply First, options the the
of months. NARCAN the over approximately critical next Spray exercising a SNS the of received the contract we a helping Secondly, this Nasal XX the caregivers opioid the need worsening and our ensure product Also funding midst the team AVXXXX in at patients $XXX of crisis hands expectations procurement who above and continues to additional gets modification perform it. well for in of doses million valued
Phase III Emergent own. first funded chikungunya VLP, development our our III milestone launched program also trial vaccine Phase We its for has for pivotal drug on because us that CHIKV a it's the key
importantly, Winnipeg. it our multiyear to and critical our mRNA in More a COVID-XX operations at progressing we our site threats underscores health pipeline commitment franchise. candidate expanding programs grow our health And CDMO vaccine finally, Therapeutics' Providence produce public securing to contract our of pursuit in travel to vaccines new continue
strategy As remains and core model strong. these diversified business highlights demonstrate, our
work that order will widespread and CIADM was related task Department unforeseen and contract capability have needed including the to end program of the We're all response. Health respond threat the following honor done over manufacturing to task to last of under HXNX to to in orders have pandemic. our the the The Services years agreed And addition, In in employees an partnership the announcing out today agreement CIADM initiated you'll COVID-XX our issued close we're proud public nine all program. of commitments. mutually in shortage CIADM the recognition Human influenza of and our the obligations domestic recall that health of Emergent open base XXXX
needed innovative all an case of the to emergency. investments maintain CIADM program operational of idea and necessary by administrations fell execution of what an capability short While the was in
the attempted just remaining swiftly incredible made responded meet engaging to frame when in in progress time we of fact, before never program. needs pandemic the very our struck, conditions. challenging two COVID issues, was and Emergent of one a original Despite the several under the facilities government's partners In
the our the government of included: for Rockville both Our in direct COVID-XX AstraZeneca work space activities. manufacturing drug included in sites; drug substance for the capital capacity reserved additional product in investment a fill/finish capacity reserved Camden Bayview; a the BARDA at finally, in CIADM sites; various program reservation at and by with candidates a under and therapeutic our and These Rockville at Camden COVID-XX Camden. Bayview, of space number manufacturing
not CIADM with work Johnson always of our Johnson the part was our and program work expected affect to under decision our year this & was the COVID-XX never as As a contracting. end reminder, it CIADM does importantly
mentioned our facility. that equivalents the in And and dose J&J vaccine collaboration Bayview as continue vaccine to extremely XXX produce top our with proud substance we're will drug AstraZeneca We I for at call, addition COVID-XX of to over has million distribution. their the at of contributed COVID-XX global
in program So work government while order of. is we the the to program and year purpose that related conclude importantly the bring been of contracts accomplished enhancing important and from team's entire our one impact past CIADM committed had closure in and said with under organization and our yet. learning done earlier to the our better. the Despite not and the mission of proud the to be team's it involvement our life task our we're be critically we I'm served chapter in the the positive needs even that on this a setbacks in globe of protecting important resilience the millions lives steadfast proud US and we immensely to business, across
forward, we we ahead opportunities entire look we're business. the optimistic encouraged about and As see our across
me our business Let strategy. changes implemented of in support we've to recent now pivot
business new services head accurately innovator unit. future. complexity by recruit business; will drive which pharma the breadth our Doug substance, all The business; to their vaccines expand will multiple Chief and government better Paul the points are: running and devices for remains customers who previously three CDMO now sharing of to who products. vaccines seek development, The services service be Doug's our or on under and will team previously our as the with opportunities. on previously business, one by White, medical opportunity to continue commercial three structure depth This we've or business new biotech across units, efficiently were Williams or be will our Spray, customers business, quarter essentially other led portfolio the in unchanged. MCM types. This these Nasal and products and experience the acquired the drug business They newly touch NARCAN continuing strategic customer on markets the we're units. each operating by During to as countermeasure The business business distinct business core commercial services capabilities. manufacturing one which Havey. and integrate going customer newly of travel will capabilities well our clear, similar into the of different and the pieces now product core into government provides positioning multiple business serve have To was Officer, of providing business focused drug that new put Operating as skills commercial facing the government or created change report ran an includes market operational organizational to be that us investment led umbrella reduces to unit. the and and structure lines shifted Adam this or capitalize our He CDMO
Overall for will R&D foundation the As committee innovation positions and creating for team led structure on execute new by the centralized programs, new R&D govern strengthening development who and success, deliver growth. that Laura previously product opportunities science ran established Dr. our unit. We're a and we providing and therapeutics this portfolio. effectively to also cross-functional our our business plan us Saward, long-term a strategic
operational getting highlights. to the So back
and implementation Bayview facility and permission FDA's the of J&J's at to following As production enhancements our mentioned resumed July, we of I COVID-XX quality vaccine the late rigorous restart. comprehensive in
five data We with to independent the quality additional all and Over transfer. teams batch procedures, consultancy, overhaul support recognized improvements our and and millions operations now of is reviewing training, step to and processes make oversee facilities, integrity in to release practices, upgrade are who J&J lab of in invested significant the certifications who added our expert quality implement we've keeping, materials testing. personnel to for the a control from Emergent months, last record along any and dollars performing control cleaning oversight prior batches. bring and colleagues took
J&J We closely FDA work increasing the and to our with production these continue consistent toward procedures. level new with
whose of that to accelerated clinical the is stage XX want months a Finally, production. last much poised to that support our facility scale Bayview transformation I team to larger work around efforts from the over one our facility commend the
to countermeasures Now our medical moving core government business. or
US our our exercise XX the that months. filed to option for exercised existing contract Our extension biologic and work remains the we the US a agents and A our Americans also against XX-year announced other smallpox US previously to of Strategic next National under government final option We helping up valued we approximately next anthrax $XXX doses AVXXXX priority top therapeutic, anthrax company. for million that and next-generation VIGIV. funded, recently secured Recall vaccine candidate, Category with government Stockpile exercising the at contract term protect ACAMXXXX supply the the the the next smallpox, the over the for government under
reminder, on a current regulatory full we path that As facilitates seek pleased ongoing AVXXXX. for to announce SNS, while by the AVXXXX FDA for the updates the I'm And contract two approval. to procurement end today important
BLA agreed the rolling to FDA the First, of the or the our FDA request as in the waiting We initiating BLA has than timing, review submit is completed rolling for The on to Based FDA the BLA mid-December. to this allows anticipate us they're late BLA. compiled. rather entire review XXXX until XXXX. a application the by we sections in AVXXXX of early anticipate package submission approval
designation has well approval. incentives development the fee as a Second, filing BLA marketing AVXXXX. as for provides potential including drug orphan designation seven-year of the upon FDA waiver granted regulatory exclusivity This
X,XXX and our help sites initiated significant XX the disease. candidate. in immunogenicity currently to chikungunya US our that the made we The I'd based growth We the pipeline immunization milestone against recently coming on chikungunya we fuel Phase forward make is look possible long-term who months. program virus-like to the pivotal active for who've development front are company. safety of the updating study study you particle will teams the for only participants VLP this this R&D across expects and dose as congratulate like vaccine in organization, our advancing candidate progress. X vaccine development the CHIKV in enroll single to On
growth the launch potential have the continued as across well our I of contribution over focused year, Finally, programs chemical of our few as studies other remain I with Phase the on threats, effect next the on R&D could they auto-injector platform a and the launch by coming years. -- anticipated encouraged the in programs our progress
to I want our that growth continue business. both Moving next we related this CDMO to and see to beyond. to in pandemic highlight area the
existing to continue clients, as We both small, from large-sized companies and receive other mid and prospects new interest as and organizations. from governments well
including drug development of business substance and drug service pillars Importantly, we're winning packaging. new all services, three across product drug
example, and For development three and the valued for service existing an baseline demonstrating of vaccine our new our its model value off Providence Winnipeg facilities. million this $XX of agreement during new portions support of Therapeutics quarter out uses we molecule-to-market five-year agreement customers. Building Gaithersburg capabilities, with a is integrated mRNA our signed at of agreement the all integrated to
We health of ever. With will opioid is maturation as threat and this continue the public to core cultivate our epidemic NARCAN strong growth, Nasal respect expansion to the focus by as on Spray, posed business.
dangers efforts NARCAN Our ensure worked opioids. through our work committed nationwide. NARCAN, outreach overdoses devastate as public and Spray available remain the campaigns team of Nasal elevate has to not to to is crisis, awareness on We to this affordable NARCAN combating but tirelessly only communities that of through families continue and also and
oral the this US on Court of final ongoing On held that Circuit litigation X August patent recall of Appeals the arguments front, infringement year.
up we this a could continue the court end decision believe is to year. come timing appellate the by to While of
in of Narcan company, an Importantly, impacting significant Longer confident our see broadly to market and we opioid-related portfolio more a we authorized are entry and our of event in our health. are core of generic the prepared product a share. portfolio to large a public maintain solutions generics partnership launch with component ability term in generic
me updates. update important corporate let Finally, two
programs; important in These we to provide a pursue decided in opportunity Head that communities an social talented search pleased team and To month. on governance sustainability to announce to of a remains poised external personnel intend that environmental, and our Global line our confident, into left quality that volunteer wanted the Mary advancements previously our also publish employee-focused insight our new resilient meantime, a has quality the of of the and our safety our human charitable product The ESG has our for third Oates, that dedicated results front conducting I'm operational Head for career Global In Quality. as We're business patient and Quality Emergent. report our I'm quarter our continue our principles programs; inaugural strategy. standards; and conclude and with demonstrate, months. our growth, report and will and professionals corporate employees; last safeguard business environment as First, several existing health made our and this new later the to to and of well note or practices. will include: practices. ethics work I capital governance
capital We value. turn continue shareholder through potential Rich? the for us will to our on detailed opportunities aimed who deployment take organic enhanced over path of the and all generating both that I'll M&A the informed results quarter. With call by prudent Rich, at
